Phathom Pharmaceuticals (PHAT) Revenue & Revenue Breakdown
Phathom Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$55.25M
Latest Revenue (Q)
$39.50M
Phathom Pharmaceuticals Revenue by Period
Phathom Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $55.25M | 8001.47% |
| 2023-12-31 | $682.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Phathom Pharmaceuticals generated $55.25M in revenue during NA 2024, up 8001.47% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $39.50M | 38.51% |
| 2025-03-31 | $28.52M | -3.86% |
| 2024-12-31 | $29.66M | 81.41% |
| 2024-09-30 | $16.35M | 123.27% |
| 2024-06-30 | $7.32M | 283.05% |
| 2024-03-31 | $1.91M | 180.35% |
| 2023-12-31 | $682.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Phathom Pharmaceuticals generated $39.50M in revenue during Q2 2025, up 38.51% compared to the previous quarter, and up 2066.06% compared to the same period a year ago.
Phathom Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.70B | $710.30M |
| MRVI | Maravai LifeSciences | $259.19M | $47.40M |
| DNA | Ginkgo Bioworks | $227.04M | $48.32M |
| IOVA | Iovance Biotherapeutics | $164.07M | $49.32M |
| VIR | Vir Bio | $74.20M | $1.21M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $39.50M |
| KURA | Kura Oncology | $53.88M | $14.11M |
| EYPT | EyePoint Pharmaceuticals | $43.27M | $5.33M |
| PROK | ProKidney | $76.00K | $221.00K |
| BBOT | BridgeBio Oncology Therapeutics | - | - |
| BCAX | Bicara Therapeutics | - | - |